Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis

Song, Yang; Sx, Zhong; Yao, Lei; Cai, Qing-Qing; Zhou, Jing; Ss, Huo; Ss, Li

doi:10.1111/j.1468-3083.2010.03785.x

Cited by 26 publications

(20 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The intermittent administration of itraconazole in pulses of 400 mg/day orally for 1 week has also been studied (27). A randomized controlled study comparing the safety and efficacy of an itraconazole pulse regimen to a continuous regimen for cutaneous sporotrichosis found similar results for both groups (238). Potassium iodide and itraconazole are contraindicated in pregnant women.…”

Section: Treatmentmentioning

confidence: 99%

Sporothrix schenckii and Sporotrichosis

Barros

Paes²,

Schubach³

2011

Clin Microbiol Rev

532

677

View full text Add to dashboard Cite

SUMMARY Sporotrichosis, which is caused by the dimorphic fungus Sporothrix schenckii , is currently distributed throughout the world, especially in tropical and subtropical zones. Infection generally occurs by traumatic inoculation of soil, plants, and organic matter contaminated with the fungus. Certain leisure and occupational activities, such as floriculture, agriculture, mining, and wood exploitation, are traditionally associated with the mycosis. Zoonotic transmission has been described in isolated cases or in small outbreaks. Since the end of the 1990s there has been an epidemic of sporotrichosis associated with transmission by cats in Rio de Janeiro, Brazil. More than 2,000 human cases and 3,000 animal cases have been reported. In humans, the lesions are usually restricted to the skin, subcutaneous cellular tissue, and adjacent lymphatic vessels. In cats, the disease can evolve with severe clinical manifestations and frequent systemic involvement. The gold standard for sporotrichosis diagnosis is culture. However, serological, histopathological, and molecular approaches have been recently adopted as auxiliary tools for the diagnosis of this mycotic infection. The first-choice treatment for both humans and cats is itraconazole.

show abstract

Section: Treatmentmentioning

confidence: 99%

Sporothrix schenckii and Sporotrichosis

Barros

Paes²,

Schubach³

2011

Clin Microbiol Rev

532

677

View full text Add to dashboard Cite

show abstract

“…Bonifaz et al [58] showed that pulse itraconazole was effective in treating cutaneous sporotrichosis. In a comparative study, Song et al [59] demonstrated similar efficacy and safety of itraconazole pulse regimen (200 mg bd for 1 week with a 3 week break) to the continuous (100 mg bd) regimen. Terbinafine 250 mg daily is equally efficacious as itraconazole 100 mg daily for cutaneous sporotrichosis [60] and has also been shown to be a well tolerated alternative in cases when itraconazole is contraindicated or resulted in significant drug interactions [61].…”

Section: Sporotrichosismentioning

confidence: 94%

Skin and subcutaneous infections in south-east Asia

Nor

Baseri

2015

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Different drug protocols are used for the treatment of sporotrichosis and include terbinafine, potassium iodide, itraconazole, fluconazole, and the amphotericin B (Song et al, 2011). Adverse events, as vomiting and diarrhea, nausea, headache, hypersensitivity reactions, abdominal pain, and liver dysfunction, can occur (Lopez-Romero et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

The Efficacy of Humanized Antibody against the Sporothrix Antigen, gp70, in Promoting Phagocytosis and Reducing Disease Burden

et al. 2017

View full text Add to dashboard Cite

Sporotrichosis is a subcutaneous mycosis distributed worldwide and is frequently reported in countries with tropical climates, as Latin America countries. We previously demonstrated that mice with sporotrichosis produce specific antibodies against a 70-kDa fungal protein, indicating that specific antibodies against this molecule may help to control the sporotrichosis. IgG1 monoclonal antibody was generated, and called mAbP6E7, in mice against a 70-kDa glycoprotein (gp70) of S. schenckii. The mAbP6E7 showed prophylactic and therapeutic activity against sporotrichosis. However, this antibody has a murine origin, and this can generate an immune response when administered to humans, precluding its use for a prolonged time. For its possible use in the treatment of human sporotrichosis, we humanized the mAbP6E7 by genetic engineering. Once expressed, the humanized antibodies had good stability and were able to bind to the 70-kDa cell wall antigens of Sporothrix schenckii and S. brasiliensis. The humanized P6E7 were able to opsonize S. schenckii yeasts, thus increasing the phagocytic index in human monocyte-derived macrophages. The treatment with humanized P6E7 decreased fungal burden in vivo. These data suggest that humanized P6E7 may have a therapeutic role in sporotrichosis.

show abstract

Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis

Abstract: The efficacy and safety of Itraconazole pulse regimen for cutaneous sporotrichosis were similar to the continuous regimen. It is an effective and safe alternative treatment for cutaneous sporotrichosis, which can also lower the cost by decreasing the number of capsules.

Cited by 26 publications

References 21 publications

Sporothrix schenckii and Sporotrichosis

Sporothrix schenckii and Sporotrichosis

Skin and subcutaneous infections in south-east Asia

The Efficacy of Humanized Antibody against the Sporothrix Antigen, gp70, in Promoting Phagocytosis and Reducing Disease Burden

Contact Info

Product

Resources

About